ArticleJournal of the National Cancer Institute2015
Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy.
Article in Journal of the National Cancer Institute, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03562871 (An Open-label, Randomized, Phase I/II Trial Investigating the Safety and Efficacy of IO102 in Combination With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment for Patients With Metastatic Non-Small Cell Lung Cancer), which is not on this map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-label, Randomized, Phase I/II Trial Investigating the Safety and Efficacy of IO102 in Combination With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment for Patients With Metastatic Non-Small Cell Lung Cancer
Who cites it
31 citing papers in PubMed, 43 citations in OpenAlex.
- Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond.Signal transduction and targeted therapy · 2026Review
- Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.Journal of hematology & oncology · 2025Review
- Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab.Journal for immunotherapy of cancer · 2023Article
- Tumor microenvironment antigens.Seminars in immunopathology · 2023Review
- Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells.Journal for immunotherapy of cancer · 2022Article
- An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma.Oncoimmunology · 2021Article
- Peptide vaccination directed against IDO1-expressing immune cells elicits CD8Journal for immunotherapy of cancer · 2020Article
- The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines.Oncoimmunology · 2020Article
- Endoplasmic Reticulum-Associated Degradation-Dependent Processing in Cross-Presentation and Its Potential for Dendritic Cell Vaccinations: A Review.Pharmaceutics · 2020Review
- Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope.Cancer immunology, immunotherapy : CII · 2019Review
- Anti-regulatory T cells are natural regulatory effector T cells.Cell stress · 2019Article
- Current Perspectives in Cancer Immunotherapy.Cancers · 2019Review
- Inflammation induced PD-L1-specific T cells.Cell stress · 2019Article
- Peripheral memory T cells specific for Arginase-1.Cellular & molecular immunology · 2019Article
- The targeting of tumor-associated macrophages by vaccination.Cell stress · 2019Article
- Cancer immune therapy for lymphoid malignancies: recent advances.Seminars in immunopathology · 2019Review
- The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer.Frontiers in immunology · 2019Review
- Anti-cancer immunotherapy: breakthroughs and future strategies.Seminars in immunopathology · 2019Article
- The T-win® technology: immune-modulating vaccines.Seminars in immunopathology · 2019Review
- Modeling Macrophage Polarization and Its Effect on Cancer Treatment Success.Open journal of immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating T cells that specifically target normal self-proteins expressed by regulatory immune cells were first described in patients with cancer, but can also be detected in healthy individuals. The adaptive immune system is distinguished for its ability to differentiate between self-antigens and foreign antigens. Thus, it was remarkable to discover T cells that apparently lacked tolerance to important self-proteins, eg, IDO, PD-L1, and FoxP3, expressed in regulatory immune cells. The ability of self-reactive T cells to react to and eliminate regulatory immune cells can influence general immune reactions. This suggests that they may be involved in immune homeostasis. It is here proposed that these T cells should be termed antiregulatory T cells (anti-Tregs). The role of anti-Tregs in immune-regulatory networks may be diverse. For example, pro-inflammatory self-reactive T cells that react to regulatory immune cells may enhance local inflammation and inhibit local immune suppression. Further exploration is warranted to investigate their potential role under different malignant conditions and the therapeutic possibilities they possess. Utilizing anti-Tregs for anticancer immunotherapy implies the direct targeting of cancer cells in addition to regulatory immune cells. Anti-Tregs provide the immune system with yet another level of immune regulation and contradict the notion that immune cells involved in the adjustment of immune responses only act as suppressor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.